Objectives: This study aimed to evaluate the prolonged therapeutic effects of a 35 kDa molecular weight hyaluronan fragment (HA35) in alleviating pain associated with myofascial pain syndrome (MPS). Hyaluronan interac...Objectives: This study aimed to evaluate the prolonged therapeutic effects of a 35 kDa molecular weight hyaluronan fragment (HA35) in alleviating pain associated with myofascial pain syndrome (MPS). Hyaluronan interacts with various receptors in the human body, including CD44, LYVE-1, RHAMM, and TLR2, and is well-known for its analgesic effects when used in intra-articular or ultrasound-guided nerve trunk injections. Studies have shown that hyaluronidase cleaves high molecular weight HA to generate HA35, a low molecular weight fragment with enhanced tissue permeability, capable of binding to HA receptors on cell surfaces to produce broad-spectrum analgesic effects. Methods: Ten patients diagnosed with MPS were treated and assessed in this study. HA35 was administered through injection at a dosage of 100 mg daily for 15 days. Patients evaluated their MPS, overall pain levels, and treatment satisfaction using the Numerical Pain Rating Scale (NPRS), the Global Pain Scale (GPS), and the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Follow-up evaluations were performed three months post-treatment to assess the duration of therapeutic effects. Results: Significant improvements were observed in NPRS, GPS, and TSQM scores both during and after the treatment period (P Conclusions: HA35 provides effective and sustained relief from pain associated with MPS, demonstrating a prolonged therapeutic benefit.展开更多
Transvaginal oocyte retrieval (TVOR) is a common yet painful procedure in assisted reproductive technologies (ART) like in vitro fertilization (IVF). Effective pain management during and after TVOR is essential, parti...Transvaginal oocyte retrieval (TVOR) is a common yet painful procedure in assisted reproductive technologies (ART) like in vitro fertilization (IVF). Effective pain management during and after TVOR is essential, particularly since anesthesia may influence oocyte quality and treatment outcomes. This case report aims to evaluate the analgesic efficacy of 35 kDa hyaluronan fragments (HA35) to manage TVOR-associated pain. A 40-year-old patient with infertility underwent two TVOR procedures ten months apart under nearly identical preparatory conditions, including a subcutaneous injection of recombinant human chorionic gonadotropin to stimulate oocyte maturation. During the first procedure, pain management consisted of diclofenac sodium suppositories alone, while the second procedure included additional subcutaneous and topical HA35 administration alongside diclofenac sodium. The primary outcome measured was the patient’s self-reported pain level on the Numeric Pain Rating Scale (NPRS), alongside secondary indicators of postoperative recovery and discomfort. Results demonstrated that the addition of HA35 reduced the patient’s pain score by half, shortened the duration of pain, significantly improved comfort, and prevented postoperative bleeding, allowing for immediate discharge. This case suggests that HA35 may offer an effective, low-risk approach to enhance analgesia, reduce side effects, and improve patient recovery in TVOR procedures.展开更多
A new β-Ti based Ti35Nb2.5Sn/10 hydroxyapitite（HA） biocompatible composite was fabricated by mechanical milling and pulsed current activated sintering（PCAS）.The microstructures of Ti35Nb2.5Sn/10HA powder particle...A new β-Ti based Ti35Nb2.5Sn/10 hydroxyapitite（HA） biocompatible composite was fabricated by mechanical milling and pulsed current activated sintering（PCAS）.The microstructures of Ti35Nb2.5Sn/10HA powder particles and composites sintered from the milled powders were studied.Results indicated that α-Ti phase began to transform into β-Ti phase after the powders were mechanically milled for 8 h.After mechanical milling for 12 h,α-Ti completely transformed into β-Ti phase,and the ultra fine Ti35Nb2.5Sn/10HA composite powders were obtained.And ultra fine grain sized Ti35Nb2.5Sn/10HA sintered composites were obtained by PCAS.The hardness and relative density of the sintered composites both increased with increasing the ball milling time.展开更多
文摘Objectives: This study aimed to evaluate the prolonged therapeutic effects of a 35 kDa molecular weight hyaluronan fragment (HA35) in alleviating pain associated with myofascial pain syndrome (MPS). Hyaluronan interacts with various receptors in the human body, including CD44, LYVE-1, RHAMM, and TLR2, and is well-known for its analgesic effects when used in intra-articular or ultrasound-guided nerve trunk injections. Studies have shown that hyaluronidase cleaves high molecular weight HA to generate HA35, a low molecular weight fragment with enhanced tissue permeability, capable of binding to HA receptors on cell surfaces to produce broad-spectrum analgesic effects. Methods: Ten patients diagnosed with MPS were treated and assessed in this study. HA35 was administered through injection at a dosage of 100 mg daily for 15 days. Patients evaluated their MPS, overall pain levels, and treatment satisfaction using the Numerical Pain Rating Scale (NPRS), the Global Pain Scale (GPS), and the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Follow-up evaluations were performed three months post-treatment to assess the duration of therapeutic effects. Results: Significant improvements were observed in NPRS, GPS, and TSQM scores both during and after the treatment period (P Conclusions: HA35 provides effective and sustained relief from pain associated with MPS, demonstrating a prolonged therapeutic benefit.
文摘Transvaginal oocyte retrieval (TVOR) is a common yet painful procedure in assisted reproductive technologies (ART) like in vitro fertilization (IVF). Effective pain management during and after TVOR is essential, particularly since anesthesia may influence oocyte quality and treatment outcomes. This case report aims to evaluate the analgesic efficacy of 35 kDa hyaluronan fragments (HA35) to manage TVOR-associated pain. A 40-year-old patient with infertility underwent two TVOR procedures ten months apart under nearly identical preparatory conditions, including a subcutaneous injection of recombinant human chorionic gonadotropin to stimulate oocyte maturation. During the first procedure, pain management consisted of diclofenac sodium suppositories alone, while the second procedure included additional subcutaneous and topical HA35 administration alongside diclofenac sodium. The primary outcome measured was the patient’s self-reported pain level on the Numeric Pain Rating Scale (NPRS), alongside secondary indicators of postoperative recovery and discomfort. Results demonstrated that the addition of HA35 reduced the patient’s pain score by half, shortened the duration of pain, significantly improved comfort, and prevented postoperative bleeding, allowing for immediate discharge. This case suggests that HA35 may offer an effective, low-risk approach to enhance analgesia, reduce side effects, and improve patient recovery in TVOR procedures.
基金Project(ZJY0605-02) supported by the Natural Science Foundation of Heilongjiang Province,ChinaProject(310703002) supported by the National Research Foundation of Korea(NRF) grant funded Korea Government
文摘A new β-Ti based Ti35Nb2.5Sn/10 hydroxyapitite（HA） biocompatible composite was fabricated by mechanical milling and pulsed current activated sintering（PCAS）.The microstructures of Ti35Nb2.5Sn/10HA powder particles and composites sintered from the milled powders were studied.Results indicated that α-Ti phase began to transform into β-Ti phase after the powders were mechanically milled for 8 h.After mechanical milling for 12 h,α-Ti completely transformed into β-Ti phase,and the ultra fine Ti35Nb2.5Sn/10HA composite powders were obtained.And ultra fine grain sized Ti35Nb2.5Sn/10HA sintered composites were obtained by PCAS.The hardness and relative density of the sintered composites both increased with increasing the ball milling time.
